Skeletal muscle hypertrophy

Skeletal muscle hypertrophy is not a specific molecule, protein, gene, or receptor, but rather a physiological outcome describing the *increase in skeletal muscle mass or size*. It results from training, hormonal stimulation, and other stimuli that promote protein synthesis and cellular growth in muscle tissue[2][3][7]. The process involves coordinated activity of multiple molecular pathways, notably the IGF1-PI3K-Akt-mTOR signaling pathway, myostatin-Smad2/3 pathway, various transcription factors (including MEF2, SRF, and others), ribosomal biogenesis, myofibrillar expansion, sarcoplasmic volume increase, satellite cell activity, and more[1][3][5][7]. As such, “Skeletal muscle hypertrophy” refers to a **biological process or state**, not to a definable molecular target such as a receptor or enzyme. It is inappropriate to treat it as a canonical drug target or receptor for purposes of structured pharmacological databases.